FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4307078082> ?p ?o ?g. }

• W4307078082 abstract "Primary central nervous system lymphoma (PCNSL) is a rare and aggressive malignancy. Although potentially curable, its prognosis remains dismal. Its treatment is based on high-doses of methotrexate (HD-MTX) and rituximab, followed by consolidation therapy with whole-brain radiotherapy (WBRT) or autologous stem cell transplantation (ASCT). Currently, there is no consensus about the best consolidation strategy, but better outcomes with ASCT are obtained with conditioning regimens based on thiotepa, a high-cost drug with restricted use in resource-constrained settings. Latin American data on clinical outcomes, prognostic factors, and therapeutic management in PCNSL are virtually unknown.This is a retrospective, observational, and single-center study involving 47-Brazilian patients with PCNSL. We aim to assess outcomes, determine predictors of survival, and compare responses, as well as toxicities in patients consolidated with chemotherapy alone versus chemotherapy plus WBRT.The median age at diagnosis was 59 years (24-88 years), and 53.1% were male. LDH ≥ UVN occurred in 44.7%, ECOG ≥ 2 in 67.6%, and 34.1% had multifocal disease. Hemiparesis was the main clinical presentation, observed in 55.3%, 51.0% had intermediate-/high-risk IELSG prognostic score, and 57.6% had an ABC-like phenotype by IHC. With a median follow-up of 24.4 months, estimated 5-year OS and PFS were 45.5% and 36.4%, respectively. Among 40 patients treated with HD-MTX-based induction, estimated 2-year OS was 85.8% for those consolidated with WBRT plus HIDAC versus only 41.5% for those consolidated with HIDAC alone (p < 0.001). Hematologic and non-hematologic toxicities were not significant, and severe cognitive impairment occurred in only 6.3% (3/47) of cases, all of them treated with WBRT. Age < 60 years, Hb ≥ 120 g/L and WBRT consolidation were associated with increased OS, however, LDH ≥ UVN, hypoalbuminemia, ECOG ≥ 2, Karnofsky PS < 70 and intermediate-/high-risk Barcelona score were associated with decreased OS.Combined consolidation therapy (CCT) based on WBRT plus HIDAC was associated with increased OS in PCNSL compared to isolated consolidation therapy (ICT) based on HIDAC alone. Here, severe late neurotoxicity was uncommon with this approach. These data suggest that WBRT may be an effective and safe alternative to ASCT for consolidation therapy in PCNSL, particularly in resource-constrained settings, where access to thiotepa for pre-ASCT conditioning is not universal." @default.
• W4307078082 created "2022-10-24" @default.
• W4307078082 creator A5000080683 @default.
• W4307078082 creator A5009511381 @default.
• W4307078082 creator A5018201754 @default.
• W4307078082 creator A5048717242 @default.
• W4307078082 creator A5050752361 @default.
• W4307078082 creator A5062358718 @default.
• W4307078082 creator A5067611125 @default.
• W4307078082 creator A5074581277 @default.
• W4307078082 creator A5076223036 @default.
• W4307078082 creator A5085392097 @default.
• W4307078082 creator A5086965467 @default.
• W4307078082 date "2022-10-22" @default.
• W4307078082 modified "2023-10-17" @default.
• W4307078082 title "The role of whole-brain radiotherapy (WBRT) in primary central nervous system lymphoma: is it an alternative to ASCT for consolidation following HD-methotrexate based induction in low-income settings?" @default.
• W4307078082 cites W1568033114 @default.
• W4307078082 cites W1787891555 @default.
• W4307078082 cites W1862506306 @default.
• W4307078082 cites W1949176581 @default.
• W4307078082 cites W1974404591 @default.
• W4307078082 cites W1984961360 @default.
• W4307078082 cites W1989124191 @default.
• W4307078082 cites W2019092345 @default.
• W4307078082 cites W2024292542 @default.
• W4307078082 cites W2036113778 @default.
• W4307078082 cites W2059060072 @default.
• W4307078082 cites W2091004431 @default.
• W4307078082 cites W2098683204 @default.
• W4307078082 cites W2107376308 @default.
• W4307078082 cites W2113924534 @default.
• W4307078082 cites W2116555475 @default.
• W4307078082 cites W2120766517 @default.
• W4307078082 cites W2134752602 @default.
• W4307078082 cites W2135838006 @default.
• W4307078082 cites W2149603266 @default.
• W4307078082 cites W2153847647 @default.
• W4307078082 cites W2157338776 @default.
• W4307078082 cites W2158267770 @default.
• W4307078082 cites W2159035898 @default.
• W4307078082 cites W2169143399 @default.
• W4307078082 cites W2237189228 @default.
• W4307078082 cites W2299421242 @default.
• W4307078082 cites W2303343204 @default.
• W4307078082 cites W2310716991 @default.
• W4307078082 cites W2314481096 @default.
• W4307078082 cites W2461875345 @default.
• W4307078082 cites W2662929969 @default.
• W4307078082 cites W2758825568 @default.
• W4307078082 cites W2766491362 @default.
• W4307078082 cites W2778583831 @default.
• W4307078082 cites W2794592737 @default.
• W4307078082 cites W2802009674 @default.
• W4307078082 cites W2807168335 @default.
• W4307078082 cites W2901857707 @default.
• W4307078082 cites W2917478934 @default.
• W4307078082 cites W3011562360 @default.
• W4307078082 cites W3032602515 @default.
• W4307078082 cites W3132555847 @default.
• W4307078082 cites W3174918603 @default.
• W4307078082 cites W3178168040 @default.
• W4307078082 cites W4225145837 @default.
• W4307078082 cites W4232291864 @default.
• W4307078082 doi "https://doi.org/10.1186/s13014-022-02142-y" @default.
• W4307078082 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36273167" @default.
• W4307078082 hasPublicationYear "2022" @default.
• W4307078082 type Work @default.
• W4307078082 citedByCount "1" @default.
• W4307078082 countsByYear W43070780822023 @default.
• W4307078082 crossrefType "journal-article" @default.
• W4307078082 hasAuthorship W4307078082A5000080683 @default.
• W4307078082 hasAuthorship W4307078082A5009511381 @default.
• W4307078082 hasAuthorship W4307078082A5018201754 @default.
• W4307078082 hasAuthorship W4307078082A5048717242 @default.
• W4307078082 hasAuthorship W4307078082A5050752361 @default.
• W4307078082 hasAuthorship W4307078082A5062358718 @default.
• W4307078082 hasAuthorship W4307078082A5067611125 @default.
• W4307078082 hasAuthorship W4307078082A5074581277 @default.
• W4307078082 hasAuthorship W4307078082A5076223036 @default.
• W4307078082 hasAuthorship W4307078082A5085392097 @default.
• W4307078082 hasAuthorship W4307078082A5086965467 @default.
• W4307078082 hasBestOaLocation W43070780821 @default.
• W4307078082 hasConcept C126322002 @default.
• W4307078082 hasConcept C141071460 @default.
• W4307078082 hasConcept C143998085 @default.
• W4307078082 hasConcept C2776694085 @default.
• W4307078082 hasConcept C2776755627 @default.
• W4307078082 hasConcept C2779050716 @default.
• W4307078082 hasConcept C2779338263 @default.
• W4307078082 hasConcept C2779968505 @default.
• W4307078082 hasConcept C2780653079 @default.
• W4307078082 hasConcept C2781173314 @default.
• W4307078082 hasConcept C509974204 @default.
• W4307078082 hasConcept C71924100 @default.
• W4307078082 hasConceptScore W4307078082C126322002 @default.
• W4307078082 hasConceptScore W4307078082C141071460 @default.
• W4307078082 hasConceptScore W4307078082C143998085 @default.
• W4307078082 hasConceptScore W4307078082C2776694085 @default.
• W4307078082 hasConceptScore W4307078082C2776755627 @default.
• W4307078082 hasConceptScore W4307078082C2779050716 @default.

• next